Skip to main content
Premium Trial:

Request an Annual Quote

Isis Pharmaceuticals and Nitto Denko s Solid Support and Dharmacon s DharmaFect

Premium

Isis Pharmaceuticals and Nitto Denko said this week that that have developed a new solid support for the manufacture of oligonucleotides.

According to the companies, solid support is the base structure used in the synthesis of oligonucleotides such as siRNAs. The new product, they added, is cheaper to manufacture than currently used solid supports and has the potential to increase yield.

The product will be marketed by Kinovate Life Sciences, a subsidiary of Nitto Denko. Isis will receive royalties on sales.


Dharmacon has introduced DharmaFect, a line of siRNA transfection reagents.

According to the company, the line consists of four different products that are effective in different cell types.

DharmaFect 1 exhibits the highest efficiency of siRNA delivery with the least impact on cell viability across the broadest range of cell types, said the company. DharmaFect 2 exhibits the least toxicity of all the lipids, while DharmaFect 3 delivers siRNA efficiently in certain cell lines such as LNCaP. DharmaFect 4 works well for mouse and rat cell lines, Dharmacon added.

Additional details about the DharmaFect line can be found at http://www2.dharmacon.com/catalog/category.aspx?key=26&SOURCE=0.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.